Executive summary
- Epidemiology analysis
- Global diabetes market analysis
- Insulin market analysis
- Oral antidiabetic (OAD) market analysis
- Leading players in the diabetes market
Chapter 1 Epidemiology analysis
- Summary
- Introduction
- Disease description
- Type 1 diabetes
- Type 2 diabetes
- Current and future prevalence of diabetes
- Diagnosis
- Fast-track review for diabetes drugs
- Current and future treatment patterns
- Insulin prescribing
- TZD prescribing
Chapter 2 Global diabetes market analysis
- Summary
- Introduction
- History of antidiabetic drugs
- Current growth drivers
- Insulins
- TZDs
- Combination therapies
- Future growth drivers
- Non-injected insulin
- Inhaled insulins
- Oral insulins
- Insulin patches
- Dual PPAR agonists
- GLP-1 agonists and DPP IV inhibitors
- GLP-1 agonists
- DPP IV inhibitors
- Amylinomimetic agents
Chapter 3 Insulin market analysis
- Summary
- Introduction
- Insulin categories and sales
- Company market share
- Brand market share and sales
- Human Insulins
- Brand analysis
- Humulin (human insulin)
- NovoLin (human insulin)
- Fast-acting human insulin analogs
- Brand analysis
- Humalog (insulin lispro)
- NovoLog (insulin aspart)
- Apidra (insulin glulisine)
- Long-acting insulin analogs
- Brand analysis
- Lantus (insulin glargine)
- Levemir (insulin detemir)
Chapter 4 Oral antidiabetic (OAD) market
- analysis
- Summary
- Introduction
- OAD categories and sales
- Company market share
- Sulfonylurea products
- Brand market share and sales
- Brand analysis
- Amaryl (glimepriride)
- Glucotrol XL (glipizide)
- Biguanide products
- Brand market share and sales
- Brand analysis
- Glucophage & Glucophage XR (metformin)
- Combined sulfonylurea & biguanide products (and other combination
- therapies)
- Sulfonylurea + biguanide single-pill combination drugs
- Glucovance (glyburide + metformin)
- TZD + other OAD single-pill combination therapies
- Thiazolidinedione (TZD) products
- Brand market share and sales
- Brand analysis
- Drug analysis
- Actos (pioglitazone)
- Avandia (rosiglitazone)
- Avandamet (rosiglitazone + metformin)
- Alpha glucosidase inhibitor (AGI) products
- Brand market share and sales
- Brand analysis
- Precose/Glucobay (acarbose)
- Basen (voglibose)
- Glyset/Diastabol (miglitol)
- Other OAD products (the prandial glucose regulators)
- Brand market shares and sales
- Brand analysis
- Prandin/NovoNorm (repaglinide)
- Starlix (nateglinide)
Chapter 5 Leading players in the diabetes
- market
- Summary
- Introduction
- Eli Lilly
- Therapeutic focus
- Insulin market share
- Marketed products
- R&D pipeline
- Exenatide (synthetic exendin-4)
- Ruboxistaurin
- Pulmonary insulin (AIR)
- Oralin
- LY-818 (naveglitazar)
- Novo Nordisk
- Therapeutic focus
- Insulin market share
- Marketed products
- R&D pipeline
- NovoMix 50 and 70 (NN1185): Injectable insulin formulations
- AERx iDMS (NN1998): An inhaled insulin
- Liraglutide (NN2211)
- Sanofi-Aventis
- Therapeutic focus
- Insulin and OAD market shares
- R&D pipeline
- Exubera
- DiaPep277
- Takeda
- Therapeutic focus
- OAD market share
- Marketed products
- R&D pipeline
- Actos/metformin combination
- ATL-962
- TAK-559
- TAK-654
- TAK-428
- GlaxoSmithKline
- Therapeutic focus
- OAD market share
- Marketed products
- R&D pipeline
- Avandaryl
- Avandamet XR
- HIM-2
- 677954
- Bristol-Myers Squibb
- Therapeutic focus
- OAD market share
- Marketed products
- R&D pipeline
- Muraglitazar
- Basulin
- Inhaled Insulin
- Pfizer
- Therapeutic focus
- Marketed products
- R&D pipeline
- Exubera
- Novartis
- Therapeutic focus
- Marketed products
- R&D pipeline
- LAF237
- Merck KGaA
- Therapeutic focus
- Marketed products
- R&D pipeline
- Index
List of Figures
- Figure 1.1: Prevalence of obese and overweight adults in US, 1976-2000
- Figure 1.2: Proportion of type 2 diabetics diagnosed, 2003
- Figure 1.3: Management of type 2 diabetes by physician type, 2003
- Figure 1.4: Proportion of drug treated type 2 diabetics treated with insulin in monotherapy or combination, 2003
- Figure 2.5: Development timeline for antidiabetic drug classes, 1920-2004
- Figure 2.6: Overview of diagnosis rates, treatment rates and insulin prescribing trends in six major markets, 2003
- Figure 2.7: Approved combination therapies for type 2 diabetes, 2003
- Figure 2.8: Positive and negative developments influencing the antidiabetics market, 2004 & forwards
- Figure 2.9: Overview of the non-invasive insulin pipeline, 2004
- Figure 3.10: Insulin brands by company and type, 2004
- Figure 3.11: US/European market share of leading insulins (%), 1999-2003
- Figure 3.12: Humulin SWOT analysis
- Figure 3.13: NovoLin SWOT analysis
- Figure 3.14: Humalog SWOT analysis
- Figure 3.15: NovoLog SWOT analysis
- Figure 3.16: Apidra SWOT analysis
- Figure 3.17: Lantus SWOT analysis
- Figure 3.18: Levemir SWOT analysis
- Figure 4.19: Sales of OAD categories in Europe and US ($m), 2003
- Figure 4.20: Global market share of leading sulfonylureas (%), 1999-2003
- Figure 4.21: Amaryl SWOT analysis
- Figure 4.22: Glucotrol XL SWOT analysis
- Figure 4.23: Global market share of leading biguanides, 1999-2003
- Figure 4.24: Glucophage XR SWOT analysis
- Figure 4.25: Glucovance SWOT analysis
- Figure 4.26: US/European market share of leading TZDs (%), 1999-2003
- Figure 4.27: Actos SWOT analysis
- Figure 4.28: Avandia SWOT analysis
- Figure 4.29: Avandamet SWOT analysis
- Figure 4.30: US/European market share of leading AGIs (%), 1999-2003
- Figure 4.31: Precose/Glucobay SWOT analysis
- Figure 4.32: Basen SWOT analysis
- Figure 4.33: US/European market share of leading PGRs (%), 1999-2003
- Figure 4.34: Prandin/NovoNorm SWOT analysis
- Figure 4.35: Starlix SWOT analysis
- Figure 5.36: Eli Lilly s therapeutic focus, 2003-2010
- Figure 5.37: Novo Nordisk s therapeutic focus, 2003 and 2010
- Figure 5.38: Sanofi-Aventis therapeutic focus, 2003 & 2010
- Figure 5.39: Takeda s therapeutic focus, 2003 & 2010
- Figure 5.40: GSK s therapeutic focus, 2003 & 2010
- Figure 5.41: BMS s changing therapeutic focus, 2003-2010
- Figure 5.42: Pfizer s changing therapeutic focus, 2003-10
- Figure 5.43: Merck KGaA s changing therapeutic focus, 2003 & 2010
List of Tables
- Table 1.1: Prevalence of Type 2 diabetes (m), 2003-2012
- Table 1.2: US and European Sales by Drug Class ($m), 2002-2003
- Table 2.3: US/European sales category totals ($m), 2002-2003
- Table 3.4: US/European Sales of insulins by category ($m), 2002-2003
- Table 3.5: Insulin market share by company and territory (%), 2002-2003
- Table 3.6: Sales of leading insulins by country ($m), 2002-2003
- Table 3.7: Branded human insulins
- Table 3.8: Branded fast-acting human insulin analogs
- Table 3.9: Branded long-acting human insulin analogs
- Table 4.10: Frequency and level of dose of OADs
- Table 4.11: US/European OAD category market share (%), 2002-2003
- Table 4.12: US/European OAD Market Share by Company (%), 2002-2003
- Table 4.13: Sales of leading sulfonylureas by country ($m), 2002-2003
- Table 4.14: Branded sulfonylureas
- Table 4.15: Sales of leading biguanides by country ($m), 2002-2003
- Table 4.16: Branded biguanides
- Table 4.17: Proportion of patients receiving monotherapy versus combination therapy treatment (%), 2003
- Table 4.18: US/European sales of sulfonylurea + biguanide single-pills ($m), 1999-2003
- Table 4.19: Sales of leading TZDs by country ($m), 2002-2003
- Table 4.20: Branded TZDs
- Table 4.21: Sales of leading AGIs by country ($m), 2002-2003
- Table 4.22: Branded AGIs
- Table 4.23: Sales of leading PGRs by country (%), 2002-2003
- Table 4.24: Branded PGRs
- Table 5.25: US/European diabetes market share by company (%), 2002-2003
- Table 5.26: US Insulin Market Share by Company (%), 2002-2003
- Table 5.27: US/European sales of Eli Lilly s marketed diabetes portfolio ($m), 2002-2003
- Table 5.28: Projected sales of Eli Lilly s diabetes R&D pipeline ($m), 2007 & 2010
- Table 5.29: European insulin market share by company (%), 2002-2003
- Table 5.30: US/European sales of Novo Nordisk s marketed diabetes portfolio ($m), 2002-2003
- Table 5.31: Projected sales of Novo Nordisk s diabetes R&D pipeline ($m), 2007 & 2010
- Table 5.32: US/European sales of Sanofi-Aventis marketed diabetes portfolio ($m), 2002-2003
- Table 5.33: Projected sales of Sanofi-Aventis diabetes R&D pipeline ($m), 2003 & 2010
- Table 5.34: US/European sales of Takeda s marketed diabetes portfolio ($m), 2002-2003
- Table 5.35: Projected sales of Takeda s diabetes R&D pipeline ($m), 2007 & 2010
- Table 5.36: US/European sales of GSK s marketed diabetes portfolio, 2002-2003
- Table 5.37: GSK s diabetes R&D pipeline, 2003
- Table 5.38: US OAD Market Share by Company (%), 2002-2003
- Table 5.39: US/European sales of BMS s diabetes portfolio, 2002-2003
- Table 5.40: Projected sales of BMS s diabetes R&D pipeline ($m), 2007 & 2010
- Table 5.41: Projected sales of Merck KGaA s diabetes R&D pipeline ($m), 2007 & 2010
|
Related Report
|
View Cart
